The global latent tuberculosis infection detection market size was estimated at around USD 2.5 billion in 2021 and expected to register a significant CAGR of over 5% during the forecast period from 2022 to 2028. The significant growth in the geriatric population coupled with the increasing rate of tuberculosis among older people is a major factor driving the market growth. Furthermore, the increasing awareness towards early diagnosis of tuberculosis among people along with the rising risk of tuberculosis is further expected to drive the market growth. Moreover, the increasing awareness program by the government initiative to handle tuberculosis and the rise in novel diagnostic solutions are further anticipated to boost the market over the forecast period. For example, in September 2020, the FDA approved Oxford Immunotec’s T-SPOT.TB test for use in pediatric patients in the United States.
Market Drivers:
High Prevalence of Tuberculosis (TB): Tuberculosis is a major global health concern, with a high prevalence in many regions. LTBI detection plays a crucial role in identifying individuals who have been infected with the TB bacteria but do not show active symptoms. The need for early detection and management of LTBI drives the demand for diagnostic tests and technologies.
Government Initiatives and Programs: Governments and public health organizations across the world have implemented various initiatives and programs to control and eliminate TB. These initiatives focus on early detection and treatment of both active TB cases and LTBI. Government support and funding for LTBI detection programs create a favorable environment for the growth of the market.
Increasing Awareness and Screening Programs: Growing awareness about the risk of TB transmission and the importance of early detection has led to the implementation of screening programs. Healthcare providers and organizations are actively conducting LTBI screening among high-risk populations, such as healthcare workers, close contacts of TB patients, and individuals with compromised immune systems. The increasing number of screening programs drives the demand for LTBI detection tests.
Technological Advancements in Diagnostic Tests: Continuous advancements in diagnostic technologies have improved the accuracy and efficiency of LTBI detection tests. Newer tests, such as interferon-gamma release assays (IGRAs) and serological tests, offer advantages over traditional tuberculin skin tests (TSTs) in terms of sensitivity, specificity, and ease of administration. Technological advancements attract healthcare providers and organizations to adopt these tests, driving the market growth.
Migration and Global Travel: Migration and global travel contribute to the spread of TB infection across different regions. People moving from high TB burden areas to low burden areas or traveling internationally can carry LTBI. Screening for LTBI becomes crucial in such cases to prevent the reactivation of latent infection and the spread of TB. The need for LTBI detection in migrant populations and travelers fuels the market demand.
Occupational Health Screening: Certain occupational groups, such as healthcare workers and prison staff, have a higher risk of exposure to TB. Occupational health screening programs focus on detecting LTBI among these high-risk groups to ensure early diagnosis and appropriate preventive measures. The inclusion of LTBI detection in occupational health screening protocols drives the market growth.
Research and Development Activities: Ongoing research and development activities in the field of LTBI detection contribute to the expansion of the market. Researchers and companies are constantly working on developing innovative diagnostic technologies and improving existing tests. The introduction of new products and technologies with improved performance characteristics drives market growth.
Collaborations and Partnerships: Collaborations and partnerships between diagnostic companies, research institutions, and public health organizations facilitate the development and commercialization of LTBI detection tests. These collaborations help in the distribution and implementation of LTBI detection technologies in various healthcare settings, thereby driving market growth.
Market Snapshot:
| Benchmark Year | 2022 | ||
| Market Size | ~ USD 2.5 Billion in 2021 | ||
| Market Growth (CAGR) | > 5% (2023-2030) | ||
| Largest Market Share | lock | ||
| Analysis Period | 2020-2030 | ||
| Market Players | QIAGEN, bioMerieux, F. Hoffmann-La Roche Ltd., Abbott, and Sanofi |
Market Insights:
By test type, the TST segment held the largest revenue share of the global market in 2021
The global latent tuberculosis infection detection market is bifurcated into test type, application, end-user, and geography. On the basis of the test, the market is further segmented into tuberculin skin test (TST) and interferon-gamma released assay (IGRA). The TST segment dominated the global market in 2021 and accounted to hold a significant market share of over 60% of the global market. The higher preference for tuberculin skin tests for the detection of tuberculosis infection especially in Asia and Africa is a major factor driving the segment growth. On the other hand, the IGRA segment is estimated to register the highest CAGR over the forecast period. The increasing research & development and the increasing prevalence of HIV are some major factors expected to fuel the segment growth.
By application, the PLHIV segment is expected to grow at a highest growth rate over the forecast perido
On the basis of application, the market is segmented into household contacts with pulmonary TB, PLHIV, and others. The PLHIV (people living with HIV infection) dominated the global latent tuberculosis infection detection market in 2021 and is expected to hold the largest revenue share of around half of the market by the end of the analysis period. The segment is also estimated to register the fastest CAGR by 2028. The higher risk to develop active tuberculosis in people living with HIV infection is a major factor to drive the segment growth. According to the WHO (World Health Organization), in 2021, 1.6 million people died from tuberculosis, in which 187000 people were infected with HIV.
To know more about the research study, request sample papers
The latent tuberculosis infection detection comprehensive study analyzes industry trends, market size, competitive analysis, and market forecast – 2022 to 2028. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.
The latent tuberculosis infection detection market research report presents the analysis of each segment from 2019 to 2028 considering 2021 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2022 to 2028.
Historical & Forecast Period
- 2019-20 – Historical Year
- 2021 – Base Year
- 2022-2028 – Forecast Period
Market Segmentation:
By Test Type:
- Tuberculin Skin Test (TST)
- Interferon Gamma Released Assay (IGRA)
By Application:
- Household Contacts with Pulmonary TB
- PLHIV
- Others
By End-User:
- Diagnostic Laboratories
- Hospitals/Clinics
- Academic & Research Institutions
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Geographic Coverage:
Geographically, the latent tuberculosis infection detection market report comprises dedicated sections centering on the regional market revenue and trends. The latent tuberculosis infection detection market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The latent tuberculosis infection detection market has been extensively analyzed on the basis of various regional factors such as demographics, gross domestic product (GDP), inflation rate, acceptance, and others. Latent tuberculosis infection detection market estimates have also been provided for the historical years 2019 & 2020 along with forecasts for the period from 2022 – 2028.
Competitive Assessment:
Some of the prominent market players operating in the global latent tuberculosis infection detection market are QIAGEN, bioMerieux, F. Hoffmann-La Roche Ltd., Abbott, and Sanofi. Companies are exploring markets through expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.
Key Companies:
- QIAGEN
- bioMerieux
- Hoffmann-La Roche Ltd.
- Abbott
- Sanofi
- Oxford Immunotec USA, Inc.
- Becton, Dickinson, and Company
- Serum Institute of India Pvt. Ltd.
- Lionex GmbH
- Autoimmune Diagnostic GMBH
Key Questions Answered by Latent Tuberculosis Infection Detection Market Report
- Global latent tuberculosis infection detection market forecasts from 2022-2028
- Regional market forecasts from 2022-2028 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
- Country-level forecasts from 2022-2028 covering 15 major countries from the regions as mentioned above
- Latent tuberculosis infection detection submarket forecasts from 2022-2028 covering the market by test type, application, end-user, and geography
- Various industry models such as SWOT analysis, Value Chain Analysis about the market
- Analysis of the key factors driving and restraining the growth of the global, regional, and country-level latent tuberculosis infection detection markets from 2022-2028
- Competitive Landscape and market positioning of top 10 players operating in the market
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.4. Assumptions
2. Executive Summary
2.1. Global Latent Tuberculosis Infection Detection Market Portraiture
2.2. Global Latent Tuberculosis Infection Detection Market, by Test Type, 2021 (USD Mn)
2.3. Global Latent Tuberculosis Infection Detection Market, by Application, 2021 (USD Mn)
2.4. Global Latent Tuberculosis Infection Detection Market, by End-User, 2021 (USD Mn)
2.5. Global Latent Tuberculosis Infection Detection Market, by Geography, 2021 (USD Mn)
3. Global Latent Tuberculosis Infection Detection Market Analysis
3.1. Latent Tuberculosis Infection Detection Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition
3.5. Competitive Analysis
3.6. Porter’s Five Force Analysis
3.6.1. Bargaining Power of Suppliers
3.6.2. Bargaining Power of Buyers
3.6.3. Threat of New Entrants
3.6.4. Threat of Substitutes
3.6.5. Degree of Competition
3.7. COVID-19 Impact Analysis
4. Global Latent Tuberculosis Infection Detection Market By Test Type, 2019 – 2028 (USD Mn)
4.1. Overview
4.2. Tuberculin Skin Test (TST)
4.3. Interferon Gamma Released Assay (IGRA)
5. Global Latent Tuberculosis Infection Detection Market By Application, 2019 – 2028 (USD Mn)
5.1. Overview
5.2. Household Contacts with Pulmonary TB
5.3. PLHIV
5.4. Others
6. Global Latent Tuberculosis Infection Detection Market By End-User, 2019 – 2028 (USD Mn)
6.1. Overview
6.2. Diagnostic Laboratories
6.3. Hospitals/Clinics
6.4. Academic & Research Institutions
7. North America Latent Tuberculosis Infection Detection Market Analysis and Forecast, 2019 – 2028 (USD Mn)
7.1. Overview
7.2. North America Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
7.3. North America Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
7.4. North America Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
7.5. North America Latent Tuberculosis Infection Detection Market by Country, (2019-2028 USD Mn)
7.5.1. U.S.
7.5.1.1. U.S. Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
7.5.1.2. U.S. Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
7.5.1.3. U.S. Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
7.5.2. Canada
7.5.2.1. Canada Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
7.5.2.2. Canada Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
7.5.2.3. Canada Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
8. Europe Latent Tuberculosis Infection Detection Market Analysis and Forecast, 2019 – 2028 (USD Mn)
8.1. Overview
8.2. Europe Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
8.3. Europe Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
8.4. Europe Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
8.5. Europe Latent Tuberculosis Infection Detection Market by Country, (2019-2028 USD Mn)
8.5.1. Germany
8.5.1.1. Germany Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
8.5.1.2. Germany Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
8.5.1.3. Germany Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
8.5.2. U.K.
8.5.2.1. U.K. Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
8.5.2.2. U.K. Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
8.5.2.3. U.K. Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
8.5.3. France
8.5.3.1. France Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
8.5.3.2. France Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
8.5.3.3. France Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
8.5.4. Spain
8.5.4.1. Spain Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
8.5.4.2. Spain Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
8.5.4.3. Spain Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
8.5.5. Italy
8.5.5.1. Italy Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
8.5.5.2. Italy Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
8.5.5.3. Italy Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
8.5.6. Rest of Europe
8.5.6.1. Rest of Europe Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
8.5.6.2. Rest of Europe Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
8.5.6.3. Rest of Europe Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
9. Asia Pacific Latent Tuberculosis Infection Detection Market Analysis and Forecast, 2019 – 2028 (USD Mn)
9.1. Overview
9.2. Asia Pacific Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
9.3. Asia Pacific Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
9.4. Asia Pacific Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
9.5. Asia Pacific Latent Tuberculosis Infection Detection Market by Country, (2019-2028 USD Mn)
9.5.1. China
9.5.1.1. China Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
9.5.1.2. China Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
9.5.1.3. China Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
9.5.2. Japan
9.5.2.1. Japan Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
9.5.2.2. Japan Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
9.5.2.3. Japan Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
9.5.3. India
9.5.3.1. India Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
9.5.3.2. India Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
9.5.3.3. India Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
9.5.4. Rest of Asia Pacific
9.5.4.1. Rest of Asia Pacific Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
9.5.4.2. Rest of Asia Pacific Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
9.5.4.3. Rest of Asia Pacific Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
10. Latin America (LATAM) Latent Tuberculosis Infection Detection Market Analysis and Forecast, 2019 – 2028 (USD Mn)
10.1. Overview
10.2. Latin America Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
10.3. Latin America Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
10.4. Latin America Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
10.5. Latin America Latent Tuberculosis Infection Detection Market by Country, (2019-2028 USD Mn)
10.5.1. Brazil
10.5.1.1. Brazil Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
10.5.1.2. Brazil Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
10.5.1.3. Brazil Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
10.5.2. Mexico
10.5.2.1. Mexico Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
10.5.2.2. Mexico Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
10.5.2.3. Mexico Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
10.5.3. Rest of Latin America
10.5.3.1. Rest of Latin America Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
10.5.3.2. Rest of Latin America Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
10.5.3.3. Rest of Latin America Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
11. Middle East and Africa Latent Tuberculosis Infection Detection Market Analysis and Forecast, 2019 – 2028 (USD Mn)
11.1. Overview
11.2. MEA Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
11.3. MEA Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
11.4. MEA Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
11.5. Middle East and Africa Latent Tuberculosis Infection Detection Market, by Country, (2019-2028 USD Mn)
11.5.1. GCC
11.5.1.1. GCC Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
11.5.1.2. GCC Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
11.5.1.3. GCC Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
11.5.2. South Africa
11.5.2.1. South Africa Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
11.5.2.2. South Africa Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
11.5.2.3. South Africa Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
11.5.3. Rest of MEA
11.5.3.1. Rest of MEA Latent Tuberculosis Infection Detection Market by Test Type, (2019-2028 USD Mn)
11.5.3.2. Rest of MEA Latent Tuberculosis Infection Detection Market by Application, (2019-2028 USD Mn)
11.5.3.3. Rest of MEA Latent Tuberculosis Infection Detection Market by End-User, (2019-2028 USD Mn)
12. Company Profiles
12.1. QIAGEN
12.1.1. Business Description
12.1.2. Financial Health and Budget Allocation
12.1.3. Product Positions/Portfolio
12.1.4. Recent Development
12.1.5. SWOT Analysis
12.2. bioMerieux
12.2.1. Business Description
12.2.2. Financial Health and Budget Allocation
12.2.3. Product Positions/Portfolio
12.2.4. Recent Development
12.2.5. SWOT Analysis
12.3. F. Hoffmann-La Roche Ltd.
12.3.1. Business Description
12.3.2. Financial Health and Budget Allocation
12.3.3. Product Positions/Portfolio
12.3.4. Recent Development
12.3.5. SWOT Analysis
12.4. Abbott
12.4.1. Business Description
12.4.2. Financial Health and Budget Allocation
12.4.3. Product Positions/Portfolio
12.4.4. Recent Development
12.4.5. SWOT Analysis
12.5. Sanofi
12.5.1. Business Description
12.5.2. Financial Health and Budget Allocation
12.5.3. Product Positions/Portfolio
12.5.4. Recent Development
12.5.5. SWOT Analysis
12.6. Oxford Immunotec USA, Inc.
12.6.1. Business Description
12.6.2. Financial Health and Budget Allocation
12.6.3. Product Positions/Portfolio
12.6.4. Recent Development
12.6.5. SWOT Analysis
12.7. Becton, Dickinson, and Company
12.7.1. Business Description
12.7.2. Financial Health and Budget Allocation
12.7.3. Product Positions/Portfolio
12.7.4. Recent Development
12.7.5. SWOT Analysis
12.8. Serum Institute of India Pvt. Ltd.
12.8.1. Business Description
12.8.2. Financial Health and Budget Allocation
12.8.3. Product Positions/Portfolio
12.8.4. Recent Development
12.8.5. SWOT Analysis
12.9. Lionex GmbH
12.9.1. Business Description
12.9.2. Financial Health and Budget Allocation
12.9.3. Product Positions/Portfolio
12.9.4. Recent Development
12.9.5. SWOT Analysis
12.10. Autoimmune Diagnostic GMBH
12.10.1. Business Description
12.10.2. Financial Health and Budget Allocation
12.10.3. Product Positions/Portfolio
12.10.4. Recent Development
12.10.5. SWOT Analysis
$ 5200/- Multi User License
We understand that every business has unique requirements. This report can be customized based on:
- Deep regional & country-level market intelligence
- Application-specific and end-use industry segmentation
- Competitive landscape & strategic benchmarking
- Go-to-market and expansion strategy insights
- Custom data cuts aligned to your business goals
- Structured Primary Research Framework
- On-Demand Industry Expert Interviews Available
- Dedicated Analyst Support
- Custom Data On Request
- Post-Purchase Strategy Consultation
- Complimentary 30-min Analyst Session
- 30% of Our Clients Are Returning Enterprise Buyers
Our Clients
